Purpose of Review There have been recent advances in our understanding of cutaneous immune responses to the important human skin pathogen, Staphylococcus aureus (S. aureus). This review will highlight these insights into innate and adaptive immune mechanisms in host defense and cutaneous inflammation in response to S. aureus skin infections. Recent Findings Antimicrobial peptides, pattern recognition receptors, and inflammasome activation function in innate immunity as well as T cells and their effector cytokines play a key role in adaptive immunity against S. aureus skin infections. In addition, certain mechanisms by which S. aureus contributes to aberrant cutaneous inflammation, such as in flares of the inflammatory skin disease atopic dermatitis, have also been identified. Summary These cutaneous immune mechanisms could provide new targets for future vaccines and immune-based therapies to combat skin infections and cutaneous inflammation caused by S. aureus.
Introduction
Staphylococcus aureus (S. aureus) is the most common cause of bacterial skin infections in humans, including infections such as impetigo (superficial infection of the epidermis), cellulitis (infection spreading through dermal and subcutaneous tissue planes), ecthyma (deep ulcerative skin infections), folliculitis (infection of hair follicles), furunculosis (deep hair follicle infections also known as boils), and carbuncles (deep communicating furuncles) as well as abscesses, wounds, and ulcers [1] [2] [3] . Such infections cause between 11 and 14 million outpatient and emergency room visits and nearly 500,000 hospital admissions per year in the USA [4, 5] . In addition, the inpatient costs for S. aureus skin infections alone range from $3.2 to $4.2 billion each year in the USA [6] . Moreover, community-acquired methicillin-resistant S. aureus (CA-MRSA) strains are causing severe skin infections in healthy people outside of hospitals and becoming increasingly resistant to antibiotics, which is creating a serious public health threat [7, 8] .
An important risk factor for S. aureus skin infections is the colonization of mucosal and skin surfaces by S. aureus. By microbiologic culture techniques, S. aureus colonization is found in the anterior nares in~30% of the population (and transiently in up to 60-80% of the population), but other sites of colonization (such as the pharynx, rectal mucosa, or the skin in the inguinal region, axillae, and peri-rectum) are also common [9, 10] . Increased S. aureus skin colonization is also associated with the marked skin inflammation in disease flares of atopic dermatitis (AD) [11, 12] , which is a chronic and relapsing inflammatory skin disease affecting 15-30% of children and 5% of adults, resulting in annual healthcare costs of $5.2 billion in the USA [13] [14] [15] . However, the skin inflammation induced by S. aureus in AD was previously thought to be primarily caused by many bacterial-derived factors, such as This article is part of the Topical Collection on Immunology S. aureus cytolytic toxins that damage cells and superantigens that activate T cells, which result in the production of proinflammatory cytokines and other inflammatory mediators [16] [17] [18] .
Neutrophil responses are involved in host defense against S. aureus infections, including S. aureus skin infections. Indeed, the formation of a neutrophil abscess is a hallmark of S. aureus infections, and S. aureus is considered a classic pyogenic (pus-forming) infection. The important role of neutrophils is best exemplified by the finding that patients with congenital or acquired defects in neutrophil number or function are highly susceptible to S. aureus skin infections and other invasive infections [3] . For neutrophils to function, they must be recruited from the bloodstream to the site of the S. aureus infection where they promote their antimicrobial function via phagocytosis of the bacteria in phagosomes. Bacterial killing within the phagosomes is mediated by reactive oxygen species (ROS), antimicrobial peptides, enzymatic digestion and proteins that sequester essential nutrients [3] . Bacterial killing also occurs via the formation of neutrophil extracellular traps (NETs) [3] . Recently, there has been a focus on T cells and how they engage neutrophilic responses for enhanced clearance of S. aureus skin infections.
In an era of declining antibiotic development and rising drug resistance, a greater understanding of the immune responses that protect against S. aureus skin infections is needed to guide future host-directed therapies. This is especially relevant as all conventional antibody-based S. aureus vaccines have failed in clinical trials, including the recent clinical trial against bacteremia/deep sternal wound infections after cardiothoracic surgery in which the vaccinated patients who became infected were five times more likely to die [19] [20] [21] [22] [23] [24] . In addition, since S. aureus skin colonization is highly associated with flares of skin inflammation as in AD, a better understanding of how S. aureus promotes skin inflammation could reveal immune targets to reduce skin inflammation. Recently, there have been significant advances in the cutaneous innate and adaptive immune responses involved in host defense against S. aureus as well as advances in mechanisms by which S. aureus contributes to aberrant skin inflammation, which will be discussed in the review.
Antimicrobial Peptides
Antimicrobial peptides (AMPs) are typically less than 50 amino acids in length and have amphipathic structures that bind selectively to negatively charged bacterial membranes to promote osmotic lysis and bacterial cell death. Several types of AMPs that possess antimicrobial activity against S. aureus are produced by different cell types and play an important role in the innate immune response against S. aureus infections in the skin (Table 1) . These include β-defensins such as human β-defensin 1 (hBD1) as well as hBD2 and hBD3 (and their mouse orthologs mouse β-defensin 3 [mBD3] and mBD14), which are produced by keratinocytes and myeloid cells and have bacteriostatic and bactericidal activity against S. aureus [25] [26] [27] [28] [29] . Notably, polymorphisms in hBD1 have been linked with increased S. aureus nasal colonization [48] . β-Defensins are induced by inflammatory signals such as Toll-like receptors (TLRs, see section below) [49] [50] [51] , inflammatory cytokines such as IL-1β, IL-17, and IL-22 [52] [53] [54] , and the activation of growth factor receptors on keratinocytes, as occurs during wound healing [55, 56] . Cathelicidin (also called LL-37) is an AMP produced by keratinocytes and myeloid cells (including neutrophils) that has potent antimicrobial activity against S. aureus [27, 33, 34] . In humans, cathelicidin production by keratinocytes and monocytes/macrophages is greatly induced by exposure to vitamin D as well as various inflammatory mediators [34, 57, 58] , and vitamin D deficiency has been linked to an increase in S. aureus skin infections in children [59] . Interestingly, a recent report revealed that if a S. aureus skin infection involved the deep dermis, adipocytes were activated to produce cathelicidin, which effectively mediated bacterial clearance [60, 61••] . Human keratinocytes also produce RNase7 [38, 39] and REG3A (the mouse ortholog Reg3γ), which are also important in providing antimicrobial activity against S. aureus [40, 41] . In human sweat, the major AMP produced by eccrine glands is dermcidin, which also has potent antimicrobial activity against S. aureus [42, 43] . Many of these AMPs, including hBD2, hBD3, and dermcidin, have decreased expression in the skin of AD patients, which provides an explanation for the increased S. aureus skin colonization and S. aureus skin infections (especially impetiginization) observed in this disease [27, 42, 62] .
In addition to cells that reside in the skin, human neutrophils are rapidly recruited to the site of S. aureus skin infection, and they produce α-defensins (also known as human neutrophil peptides [HNPs] ) that are secreted into the neutrophil phagosome to promote antimicrobial activity [44] . If S. aureus bacteria enter the cytoplasm of neutrophils, about 50% of the protein fraction of human neutrophils contain calprotectin (S100A8/S100A9) which sequesters iron, manganese, and zinc to inhibit bacterial growth [46, 47] .
Many of these AMPs not only have antimicrobial activity but also promote chemotaxis of other immune cells. For example, HBDs have chemotactic activity for dendritic cells and T cells via interactions with chemokine receptors CCR2 and CCR6 [30] [31] [32] ; cathelicidin has chemotactic activity for neutrophils, monocytes, and T cells via interaction with formyl peptide receptors [35] [36] [37] ; and HNPs have chemotactic activity for macrophages, dendritic cells, and T cells [45] . Therefore, multiple different AMPs are produced by keratinocytes and stromal and resident immune cells in the skin as well as recruited neutrophils and other immune cells, which all contribute to host defense against S. aureus skin infections.
Pattern Recognition Receptors
Pattern recognition receptors (PRRs) are host cell receptors that recognize pathogen-associated molecular patterns (PAMPs) found on microorganisms, which enable PRRs to recognize foreign microbial components and initiate host defense responses. These PRRs activate different signaling pathways that ultimately result in the production of cytokines, chemokines, adhesion molecules, and AMPs involved in host defense. Several PRRs have been implicated in the recognition of S. aureus components, especially certain TLRs and nucleotide-binding oligomerization domain-containing protein 2 (NOD2) (Fig. 1) . Of the 10 known human TLRs, TLR2 is found on the cell membrane. TLR2 heterodimerizes with TLR1 to recognize triacyl lipopeptides or with TLR6 to recognize diacyl lipopeptides, including S. aureus lipoteichoic acid (which is diacylated), and interacts with co-receptors CD14 and CD36 which impact ligand specificity [63] [64] [65] . Gene polymorphisms in TLRs 1, 2, and 6 are associated with increased susceptibility to S. aureus skin infections [66] , and TLR2-deficient mice have an increased susceptibility to S. aureus skin infections [65, 67, 68] . TLRs 1, 2, and 6 are found in the cell membrane of a variety of cell types in the skin, including keratinocytes, Langerhans cells, monocytes/macrophages, dendritic cells, mast cells, endothelial cells, fibroblasts, and adipocytes. Thus, many cell types in the skin can recognize S. aureus lipopeptides and lipoteichoic acid and contribute to cutaneous host defense [69] .
In addition to TLR2, TLR9 is found in endosomal membranes, recognizes double-stranded DNA, primarily induces a type I interferon response, and has also been implicated in host defense against S. aureus infections. Human TLR9 recognizes CpG motifs of S. aureus double-stranded DNA [70] . In addition, women with a particular polymorphism in the promoter region of TLR9 resulted in decreased TLR9 expression and persistent S. aureus nasal colonization [71] . Recently, it was reported that stimulator of interferon genes (STING), a cytosolic DNA sensor (i.e., cyclic guanosine-adenosine synthase [cGAS]), suppressed TLR-induced genes in macrophages in vitro, and mice deficient in STING had enhanced clearance of a S. aureus skin infection compared with wt mice [72•] . These findings indicate that STING responds to S. aureus DNA in the cytoplasm and has an opposing role in host defense by downregulating TLR-mediated host defense mechanisms against S. aureus skin infections.
Another important PRR for S. aureus is NOD2 that recognizes the Gram-positive peptidoglycan breakdown product muramyl dipeptide (MDP), including MDP derived from S. aureus peptidoglycan [73] . In cultured keratinocytes exposed to S. aureus, inhibition or overexpression of NOD2 resulted in more or less S. aureus survival, respectively, that correlated with IL-17C expression [74] . Furthermore, mice deficient in NOD2 had an increased susceptibility to an S. aureus skin infection, which was mediated in part by reduced expression of IL-6 and IL-1β that impacted the neutrophilic response [67, 75] . Taken together, several PRRs, including TLRs 1, 2, 6 in the cell membrane, TLR9 in endosomal membranes, and STING and NOD2 in the cytoplasm, promote and regulate cutaneous host defense against S. aureus skin infections. Importantly, the cellular compartment in which these different PRRs are located and the signaling pathways these PRRs initiate are crucial in how they ultimately contribute to host defense against S. aureus skin infections. 
Inflammasomes
Our laboratory and others have found a key role for IL-1β in promoting neutrophil recruitment and host defense against S. aureus skin infections [67, 68, [76] [77] [78] . Although transcription and translation of pro-IL-1β is induced by PRRs (such as TLR2 and NOD2, as described above), inflammatory cytokines, and other mediators (such as TNF), a second signal typically mediated by inflammasome complexes is required to process pro-IL-1β into active IL-1β (as well as pro-IL-18 to active IL-18) [79] [80] [81] . These inflammasomes form complexes of proteins in the cytoplasm that undergo massive oligomerization, which ultimately results in release of mature and active IL-1β from the cell and subsequent triggering of IL-1R/MyD88-signaling [79] [80] [81] . Several reports have found that the NLRP3 (nucleotide binding domain [NOD]-, leucine-rich repeat (LRR)-, and pyrin domain-containing 3) inflammasome can be triggered by the creation of pores in the cell membrane that lead to potassium (K + ) efflux in response to the activity of S. aureus pore-forming toxins (α-, β-, and γ-toxins, and Panton-Valentin leukocidin [PVL] ) and prurinergic receptors that recognize ATP produced by the bacteria and damaged cells during an infection (such as P2X7) as well as lysosomal rupture in macrophage cultures in vitro and in mouse models of S. aureus skin infections in vivo (Fig. 2) [77, 78, [82] [83] [84] [85] [86] . The NLRP3 inflammasome has been shown to be critical for promoting IL-1β activity at the site of a S. aureus skin infection in mice by mediating neutrophil recruitment to the site of infection in the skin [67, 77] . Interestingly, NLRP3 inflammasome activity is reduced in lesional AD skin and in keratinocytes in response to Th2 cytokines (i.e., IL-4, IL-5, and IL-13, which are increased in AD affected skin [87] ), providing another mechanism for increased S. aureus colonization and S. aureus skin infections in AD.
T Cells in Host Defense Against S. aureus Skin Infections
Although enhancing opsonophagocytosis (i.e., antibodymediated phagocytosis) by inducing high titers of antibodies against bacterial surface components has been a successful vaccination approach for other bacterial pathogens, this has not been the case for S. aureus. Several vaccines targeting Fig. 1 Pattern recognition receptors that recognize components of S. aureus. Different components of S. aureus are recognized by specific pattern recognition receptors (PRRs) that include the following: TLR1/2 heterodimer that recognizes triacyl lipopeptides and is found on the cell membrane; TLR2/6 heterodimer that recognizes diacyl lipopeptides as well as lipoteichoic acid (LTA) and is found on the cell membrane; NOD2 that recognizes the S. aureus peptidoglycan (PGN) breakdown product muramyl dipeptide (MDP) and is found in the cytoplasm; TLR9 that recognizes CpG motifs of S. aureus DNA and is found in endosomal membranes; and STING that recognizes DNA (cyclic guanosine-adenosine synthase [cGAS]) and is found in the cytoplasm. TLRs and NOD2 lead to inflammatory signaling pathways such as the activation of NF-κB (nuclear factor-κB) that leads to production of proinflammatory cytokines, chemokines, adhesion molecules, and antimicrobial peptides involved in cutaneous host defense against S. aureus skin infections. STING has been shown to suppress protective TLR responses against S. aureus skin infections and thus serves as PRR that regulates cutaneous host defense mechanisms opsonophagocytosis by producing antibodies against S. aureus cell surface molecules, including capsular polysaccharides 5 and 8, clumping factor A (ClfA), and iron surface determinant B (IsdB), have all failed in human clinical trials [19] [20] [21] . Although the reason for these failures is not entirely clear, S. aureus produces many virulence factors to evade antibodymediated immune responses [88, 89] . More recent vaccination attempts have alternatively targeted the production of antibodies that neutralize S. aureus toxins and virulence factors, and such attempts are currently in various stages of preclinical and clinical development and are reviewed elsewhere [90] [91] [92] [93] .
However, there has been a major focus on T cell responses, as they might provide an alternative strategy to targeting antibody responses for an effective adaptive immune response to protect against S. aureus skin infections and other invasive infections. Several findings in humans have suggested a role for T cells in immunity to S. aureus skin infections. These findings include the following: (i) patients with autosomal dominant hyper-IgE syndrome, who are highly susceptible to recurrent Candida albicans (C. albicans) and S. aureus skin infections, were found to have a deficiency in IL-17A-and IL-17F-producing CD4 + T helper cells (i.e., Th17 cells) [94] ; (ii) rare humans identified with IL-17RA-deficiency or IL-17F-deficiency, who have an increased susceptibility to C. albicans infections and a lesser susceptibility to S. aureus skin infections [95, 96] ; (iii) patients with atopic dermatitis, who have increased S. aureus skin colonization and impetiginization, have increased Th2 cells and cytokines in their affected skin [16] [17] [18] ; and (iv) patients with HIV disease, who are highly susceptible to S. aureus skin infections, have decreased CD4+ T helper cells decreased CD4 + T helper cells in their blood [97, 98] . Similarly, in mouse models of S. aureus skin infections, IL-17A and IL-17F (primarily produced by γδ T cells) promote neutrophil recruitment, AMP production, and increased S. aureus bacterial clearance from the skin [99] [100] [101] [102] [103] , including a specific role for IL-17A in host defense against repeated S. aureus skin infection exposures [104] . Mice deficient in both IL-17A and IL-17F also develop spontaneous mucocutaneous S. aureus infections [105] and are more susceptible to S. aureus nasal colonization [106•, 107] . However, the findings in humans with primary deficiency disorders such as the aforementioned hyper-IgE syndrome, IL-17RA-deficiency, IL-1F-deficiency, and other disorders with defective IL-17 responses primarily suffer from oligomerization ultimately leading to the processing of pro-caspase-1 to active caspase-1 that cleaves pro-IL-1β into active and mature IL-1β, which then can be secreted from the cell to elicit IL-1R-dependent immune responses. It has been shown that NLRP3 inflammasome activation in response to S. aureus can be triggered by potassium (K + ) efflux, which can be initiated by pore-forming toxins (such as α-, β-, or γ-hemolysins and Panton-Valentine Leukocidin [PVL]), purinergic receptors (such as P2X7 activated by ATP released by bacteria and damaged cells during infection) and lysosomal rupture during the intracellular digestion of S. aureus bacteria in phagocytes such as macrophages mucocutaneous candidiasis rather than S. aureus skin infections [108] , suggesting that mechanisms other than IL-17 responses are crucial for durable protection against S. aureus skin infections. Notably, protection against S. aureus skin infections in patients with HIV disease was recently found to be more dependent upon IFNγ rather than IL-17 [109••] . Similarly, mice deficient in both IL-17RA and IFNγR had more severe spontaneous mucocutaneous S. aureus infections than mice deficient in IL-17RA alone [110] . Finally, we recently reported that following an initial S. aureus skin infection in mice, clonally expanded γδ T cells in skin draining lymph nodes were capable of mediating long-term memory protection lasting at least 140 days by trafficking from lymph nodes to the infected skin where they produced IFNγ and TNF to enhance the neutrophil response against a subsequent S. aureus skin challenge [111••] . Therefore, the role of T cells in immunity to S. aureus skin infections likely involves multiple T cell effector cytokines, including IL-17, IFNγ, and TNF (Fig. 3) , and these T cell responses could serve as more effective immune mechanisms to target in future vaccine efforts.
A Novel Mechanism by Which S. aureus Promotes Skin Inflammation S. aureus colonization and superficial infection (impetiginization) of the skin is associated with skin inflammation during disease flares of AD, which was previously thought to be caused by to the action of S. aureus toxins and superantigens [16] [17] [18] . In particular, superantigens of S. aureus have been shown to skew T cell responses towards Th2 cells that produce IL-4 [112] . However, our laboratory and another group simultaneously reported that IL-36R (an IL-1R family member activated by IL-36α, IL-36β, and IL-36γ that signals via the IL-1R/TLR signaling adapter molecule MyD88) was required to induce skin inflammation following S. aureus exposure to the surface of mouse skin (i.e., epicutaneous exposure) (Fig. 4) [113••, 114••] . The mechanism by which IL-36R promoted skin inflammation involved increased expression of IL-36α in keratinocytes (in part by the activity of the S. aureus-derived toxin phenol-soluble modulin α [PSMα]) that subsequently induced IL-17-producing γδ and CD4 + T cells that were essential for mediating the skin inflammation. These results likely relate to human AD because IL-36α and IL-36γ transcripts were found to be increased in the affected human skin of AD patients [115•] . In addition, increased IL-17 cytokines and increased numbers of Th17 cells were reported in the skin and peripheral blood from humans with acute AD [116, 117] . These findings extend the role of IL-36 cytokines in the skin as a prior study found that humans with loss-of-function mutations in IL-36RN, which encodes the IL-36 receptor antagonist (IL-36Ra) develop generalized pustular psoriasis [118] , and IL-36 cytokines were subsequently found to be elevated in other forms of psoriasis [119] . It should be mentioned that the anatomical site of S. aureus exposure of the skin was an important determinant in eliciting differential immune responses. As mentioned above, S. aureus epicutaneous exposure in mice resulted in IL-36-mediated skin inflammation (Fig. 4 The T cell effector cytokines IL-17A/F, IFNγ, and TNF promote antimicrobial peptide production by keratinocytes as well as the production of chemokines, cytokines, adhesion molecules, and granulopoiesis factors that promote neutrophil recruitment from the bloodstream to form an abscess to facilitate bacterial clearance. The B cell responses following a S. aureus skin infection include antibody production that promotes opsonophagocytosis (i.e., antibody-mediated phagocytosis) by monocytes/macrophages and neutrophils to help facilitate clearance of the S. aureus skin infection intradermal infection model in mice resulted in IL-1β-mediated neutrophil recruitment and abscess formation [67, 68, [76] [77] [78] . Taken together, this newly reported role for IL-36 provides a potentially important mechanism by which S. aureus exposure to the skin surface induces skin inflammation by triggering T cell IL-17 responses [120] . Future work will determine whether IL-36 could serve as a target for future biologic therapies to reduce skin inflammation in AD, psoriasis, and perhaps other inflammatory skin diseases.
Conclusions
S. aureus is an important human skin bacterial pathogen, and CA-MRSA strains are spreading through the normal human population, becoming more resistant to antibiotics and creating a serious public health concern. Recent insights have revealed key roles for AMPs, TLRs, NOD2, STING, the NLRP3 inflammasome, and T cells (and their effector cytokines IL-17, IFNγ, and TNF) in cutaneous host defense against S. aureus skin infections. In addition, S. aureus epicutaneous exposure to the skin resulted in IL-36-mediated, T cell-dependent IL-17 production that induced skin inflammation, providing a newly identified mechanism by which S. aureus induces skin inflammation in AD and potentially in other inflammatory skin diseases. These immune mechanisms might serve as more effective immune targets for the future development of vaccines and immunotherapies against S. aureus skin infections and S. aureus-associated inflammatory skin diseases. 
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